# Pulmonary Hypertension 

Pakinam Mekki

---

## Background

- Symptoms: insidious dyspnea, exertional chest pain, orthopnea, PND,
    edema

- Exam: JVD, increased P2, split S2, RV heave, TR murmur,
    hepatomegaly, ascites, edema

- Signs of RV failure: low cardiac output (hypotension, renal failure,
    hepatic congestion), arrhythmias, refractory hypoxemia (R→L shunt),
    effusions (pericardial \> pleural) 

- WHO Groups and Causes: 

    - Group 1: Pulmonary arterial hypertension (PAH): obliteration of
        blood vessels in the lung 

        - Idiopathic, heritable 

        - Drugs/toxins (methamphetamine) 

        - Associated with CTD, HIV, portal HTN, congenital heart disease,
            schistosomiasis 

        - Pulmonary veno-occlusive disease (PVOD), pulmonary capillary
            hemangiomatosis 

    - Group 2: Left heart disease: back pressure and passive congestion 

        - HFrEF, HFpEF, valvular disease, LA stiffness 

    - Group 3: Chronic lung disease: chronic hypoxemia, chronic pulmonary
        vasoconstriction 

        - COPD, ILD, OSA, chronic high-altitude, developmental lung
            disorders 

    - Group 4: Chronic thromboembolic pulmonary hypertension (CTEPH) 

    - Group 5: Multifactorial

        - Hematologic disorders, chronic hemolytic anemia, sarcoidosis,
            pulmonary Langerhans cell histiocytosis, fibrosing
            mediastinitis, metabolic disorders 

## Evaluation

- Most common reason for admission with a known diagnosis of pHTN is
    volume overload/RV failure and hypoxia

    - Consider etiology of decompensation: Progression of underlying
        disease, medication/dietary nonadherence, infection, arrhythmia,
        myocardial infarction/RV ischemia, shunting via opening a PFO as a
        release valve, pulmonary embolism

- Consult pulmonary hypertension with any questions or assistance with
    workup

- Studies to consider ordering to determine etiology of pulmonary
    hypertension

    - Labs: BNP, liver enzymes, rheumatologic serologies (ANA w/ reflex
        ENA, RF/CCP, ANCA, Scl-70, Ro/LA)

    - EKG: R-axis deviation, RBBB, increased P wave in lead II

    - CXR: increased PA and R heart border, vascular pruning

    - TTE w bubble: RVSP \>35-40, RV dilation and dysfunction, RA
        dilation, septal flattening, pericardial effusion, evaluate for L
        heart disease and shunt

    - PFT (outpatient): isolated decrease in DLCO in group I PH, TLC \<
        50%, FEV/FVC \< 70%

    - V/Q scan or CTA chest to evaluate for CTEPH

    - 6-minute walk test is prognostic, can be used to monitor response to
        therapy

    - +/- CT chest to evaluate for parenchymal lung disease

    - +/- sleep study to evaluate for OSA

    - Right heart catheterization (RHC) is the gold standard test for PH
        diagnosis and determines pre-vs post-capillary HTN (See RHC section
        in Cardiology)  

        - Nitric oxide challenge to assess for drug response

        - Fluid challenge with 500cc LR to assess left heart compliance
            \`

<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 40%" />
<col style="width: 26%" />
</colgroup>
<thead>
<tr class="header">
<th>Definitions</th>
<th>Characteristics</th>
<th>Causes</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Pre-capillary PH</td>
<td><p>mPAP &gt; 20 mmHg</p>
<p>PAWP ≤ 15 mmHg</p>
<p>PVR ≥ 3 WU</p></td>
<td>Groups 1, 3, 4, 5</td>
</tr>
<tr class="even">
<td>Post-capillary PH</td>
<td><p>mPAP &gt; 20 mmHg</p>
<p>PAWP &gt; 15 mmHg</p>
<p>PVR &lt; 3 WU</p></td>
<td>Group 2</td>
</tr>
<tr class="odd">
<td><p>Combined pre- and post-</p>
<p>capillary PH</p></td>
<td><p>mPAP &gt; 20 mmHg</p>
<p>PAWP &gt; 15 mmHg</p>
<p>PVR ≥ 3 WU</p></td>
<td>Group 2, 5</td>
</tr>
</tbody>
</table>

## Poor Prognostic Indicators for pHTN

- NYHA Functional Class (FC III-IV) - 6-minute walk test \< 300

- AKI - Hyponatremia

- Low SBP (SBP \< 90) - CTD or liver disease as etiology

- Poor hemodynamics on RHC (RAP \> 20; cardiac index \< 2)

- TTE findings - TAPSE \< 1.8, pericardial effusion, severe RV
    dysfunction

## Management

- Goal of hospitalization is to understand and optimize hemodynamics

- Overall goal- improve NYHA functional class, RV function, 6-minute
    walk test, quality of life

- General management: treat underlying cause, diuretics for right
    heart failure, goal SpO2\>90%

- PAH medicines: Consult pulmonary hypertension if considering
    starting of changing meds

- Oral treatments may be used as monotherapy or in combination 

    - Calcium-channel blockers → patients with + vasoreactive challenge 

    - NO-cGMP enhancers: PDE5-inhibitors sildenafil or tadalafil,
        riociguat 

    - Endothelin receptor antagonists (ERAs): Bosentan, macitenatan,
        ambrisentan –

- Prostacyclin analogs

    - Prostacyclin analogs increase cAMP-mediated pulmonary
        vasodilation. Side effects include jaw pain, flushing,
        arthralgia, diarrhea.

    - IV formulations are administered through a continuous pump.
        Never stop IV prostacyclins, even brief pauses can cause rebound
        vasoconstriction and death. In an emergency, can run temporarily
        through PIV

        - Epoprostenol: IV (Veletri) or inhaled (Flolan), half-life 4
            minutes.

        - Treprostinil: IV/subcutaneous/inhaled/PO, half-life 4 hours 

        - Iloprost: inhaled, half-life minutes 

        - Selexipag (Uptravi): PO, half-life hours 

- Treatment based on NYHA functional classification: 

    - Class I: no treatment or monotherapy 

    - Class II: monotherapy or combination oral therapy 

    - Class III: combination oral therapy or prostacyclin 

    - Class IV: prostacyclin +/- oral therapy 

- Lung transplant for patients who are candidates and failing maximal
    medical therapy 

- VA ECMO can be used as bridge to medical therapy or lung transplant 

- Atrial septostomy- serves as “pop-off” valve and allows for
    decompression of failing RV; used as definitive palliative procedure
    or bridge to transplant 
